REFERENCES
- Schantz S. P., Harrison L. B., Forastiere A. Cancer of the head and neck. Cancer: principles and Practice of Oncology, V. T. De Vita, S. Hellman, S. A. Rosenberg. Lippincott, Philadelphia 2001; 30: 789–917
- Everett E., Vokes E. E., Ralph R., Weichselbaum R. R., Scott M., et al. Head and neck cancer (review). N. Engl. J. Med. 1993; 328: 184–194, [CSA]
- Forastiere A. Head and neck cancer: overview of recent developements and future directions. Semin. Oncol. 2000; 27: 1–4, [INFOTRIEVE], [CSA]
- Khuri F. R., Shin D. M., Glisson B. S., Lippman S. M., Hong W. K. Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: current status and future directions. Sem. Oncol. 2000; 27: 25–33, [CSA]
- Vokes E. E., Athanasiadis I. Chemotherapy for squamous cell carcinoma: the future is now. Ann. Oncol. 1996; 7: 15–29, [INFOTRIEVE], [CSA]
- Pommier Y., Fesen M. R., Goldwasser F., Topoisomerase I I. Inhibitors: the epipodophyllotoxins, m-AMSA, and the ellipticine derivates. Cancer Chemotherapy and Biotherapy, B. A. Chabner, D. L. Longo. Lippincott-Raven, Philadelphia 1996; 435–461
- Joel S. Antitumour treatment: the clinical pharmacology of etoposide: and update. Cancer Treat Rev. 1996; 22: 179–221, [INFOTRIEVE], [CROSSREF], [CSA]
- Hande K. R. Etoposide: four decades of development of a topoisomerase II inhibitor. Europ. J. Cancer 1998; 34: 1514–1521, [CROSSREF], [CSA]
- Johnson D. H., Hainsworth J. D., Hande K. R., Greco F. A. Current status of etoposide in the management of small cell lung cancer. Cancer 1991; 67: 231–244, [INFOTRIEVE], [CSA]
- Muggia F. M., Russel C. A. New chemotherapies for ovarian cancer. Cancer 1991; 67: 225–230, [INFOTRIEVE], [CSA]
- Radice P. A., Bunn P. A., Ihde D. C. Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, Non-Hodgkin's lymphomas and other malignancies. Cancer Trat. Rep. 1979; 63: 1231–1239, [CSA]
- Ajani J. A., Ota D. M., Jackson D. E. Current strategies in the management of locoregional and metastatic gastric carcinoma. Cancer 1991; 67: 260–265, [INFOTRIEVE], [CSA]
- Kakolyris S., Samonis G., Koukourakis M., Vlachonicolis I., Chalkiadakis G., et al. Treatment of non-small—cell lung cancer with prolonged oral etoposide. Oncol. 1998; 21(5)505–508, Oct[CSA]
- Hoskins P. J., Swenerton K. D. Oral etoposide is acitve against platinum-resistent epithelial ovarian cancer. J. Clin. Oncol. 1994; 12: 60–63, [INFOTRIEVE], [CSA]
- Harstrick A., Bokemeyer C., Preusser P., Kohne-Womper C. H., Meyer H. J., et al. Phase II study of single-agent etoposide in patients with metastatic squamous cell carcinoma to the esophagus. Cancer Chemother. Pharmacol. 1992; 29: 321–322, [INFOTRIEVE], [CROSSREF], [CSA]
- Khafif A., Canfield V. A., Syzek E. J., Medina J. E. Results of phase I-II trial of concomitant hyperfractionated radiation and oral etoposide (VP-16) in patients with unresectable squamous cell carcinoma of the head and neck. Am. J. Orolaryngol. 2003; 24: 1–5, [CROSSREF], [CSA]
- Khono N., Kitahara S., Kawaida M., Ohmuma T. Prognosis after salvage chemotherapy for locally unresectable recurrent squamous cell carcinoma of the head and neck. Jpn. J. Clin. Oncol. 1999; 29: 462–466, [CROSSREF], [CSA]
- Miller A. B., Hoogstraten B., Staquet M. Reporting results of cancer treatment. Cancer 1981; 147: 207–214, [CSA]
- Gedlicka C., Formanek M., Selzer E., Burian M., Kornfehl J., et al. Phase II study with docetaxel and cisplatin in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. Oncology 2002; 63(2)145–150, [INFOTRIEVE], [CROSSREF], [CSA]
- Keane M., Karney D. N. Treatment of elderly patients with small cell lung cancer. Lung Cancer 1993; 9(suppl 1)91–98, [CROSSREF], [CSA]
- Braybrooke J. P., O'Byrne K. J., Saunders M. P., Propper D. J., Salisbury A. J., et al. A phase II study of mitomycin C and oral etoposide for advanced adenocarcinoma of the upper gastrointestinal tract. Ann. Oncol. 1997; 8: 294–296, [INFOTRIEVE], [CROSSREF], [CSA]
- Crivellari D., Veronesi A., Magri M. D., Tirelli U., Comoretto R., et al. Phase II trial of oral VP16-213 (etoposide) in patients with advanced head and neck cancer. Tumori. 1985; 71(5)499–500, Oct 31[INFOTRIEVE], [CSA]
- Grunberg S. M., Felman I. E., Gala K. V., Johnson K. B., Owens J. C. Phase II study of etoposide (VP-16) in the treatment of advanced head and neck cancer. Am. J. Clin. Oncol. 1985; 8 5: 393–395, Oct[INFOTRIEVE], [CSA]